B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches

Current Opinion in Oncology
Sally TemrazAli Shamseddine

Abstract

B-type proto-oncogene (BRAF) mutations have been observed in about 10.8% of patients with colorectal cancer (CRC). These patients do not respond to standard therapy with anti-epidermal growth factor receptor kinase (EGFR). Here we review novel BRAF inhibitors that are currently being investigated in these tumors. Clinical experience with the BRAF inhibitor vemurafenib in CRC suggests significant differences in response compared with melanoma. Based on preclinical data, resistance to BRAF inhibitors employs alternative signaling pathways that in turn induce cell proliferation and survival. Therapeutic strategies that combine BRAF inhibitors in addition to targeted therapy with anti-EGFR monoclonal antibodies and phosphoinositide 3-kinase pathway inhibitors or standard therapy have yielded promising results in preclinical models and some reported cases. Results from current clinical trials that are exploring novel BRAF inhibitors and others that employ combined therapy are eagerly awaited for the treatment of BRAF-mutated CRC. http://links.lww.com/COON/A13.

References

Mar 3, 2009·Proceedings of the National Academy of Sciences of the United States of America·Christine A PratilasNeal Rosen
Sep 8, 2010·The New England Journal of Medicine·Keith T FlahertyPaul B Chapman
Jan 21, 2011·Indian Journal of Cancer·K M GalalAbdel Monem M Mourad
Jan 22, 2011·Cancer Cell·Poulikos I Poulikakos, Neal Rosen
Jun 7, 2011·The New England Journal of Medicine·Paul B ChapmanUNKNOWN BRIM-3 Study Group
Dec 20, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Muling MaoScott Kopetz
Mar 27, 2013·Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti·B RobešováD Dvořáková
Apr 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erin M CoffeeKenneth E Hung
Apr 23, 2013·Molecular Diagnosis & Therapy·Marzena Anna LewandowskaBogdan Żurawski
Jun 13, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anna SpreaficoS Gail Eckhardt
Jul 13, 2013·Drugs·Cameron J M Wright, Paul L McCormack
Jul 25, 2013·Drugs·Anita D Ballantyne, Karly P Garnock-Jones
Oct 19, 2013·International Journal of Cancer. Journal International Du Cancer·Yusuke NakadateFumiaki Koizumi
Apr 26, 2014·World Journal of Gastroenterology : WJG·Bun KimSung Pil Hong
Jun 20, 2014·Journal of Cancer Research and Clinical Oncology·Tae Sung AhnMoo-Jun Baek
Jun 21, 2014·Cancer·Mauricio BurottoElise C Kohn
Jun 24, 2014·Cancer Control : Journal of the Moffitt Cancer Center·Richard D Hall, Ragini R Kudchadkar
Aug 7, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey KimRichard Pazdur
Aug 15, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J SorichC S Karapetis
Aug 27, 2014·Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland·W LiF Hou
Nov 29, 2014·Chinese Medical Sciences Journal = Chung-kuo I Hsüeh K'o Hsüeh Tsa Chih·Qi WangJia Wei
Jan 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M J SorichC S Karapetis

❮ Previous
Next ❯

Methods Mentioned

BETA
xenografts
xenograft

Clinical Trials Mentioned

NCT01791309
NCT02164916
NCT01750918
NCT01719380
NCT01902173

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Calcium & Bioenergetics

Bioenergetic processes, including cellular respiration and photosynthesis, concern the transformation of energy by cells. Here is the latest research on the role of calcium in bioenergetics.